237 related articles for article (PubMed ID: 8551714)
1. [Mechanism of bacterial regrowth at the sites of infection in Mycobacterium avium complex-infected mice during treatment with chemotherapeutic agents].
Sato K; Tomioka H; Maw WW; Saito H
Kekkaku; 1995 Dec; 70(12):673-8. PubMed ID: 8551714
[TBL] [Abstract][Full Text] [Related]
2. [Profiles of expression of the therapeutic efficacy of KRM-1648 in mice infected with Mycobacterium avium complex at different challenge doses].
Shimizu T; Ogasawara K; Sato K; Sano C; Tomioka H
Kekkaku; 2001 May; 76(5):413-8. PubMed ID: 11449696
[TBL] [Abstract][Full Text] [Related]
3. [Effects of half-sized secretory leukocyte protease inhibitor and Chinese traditional medicines, yokuinin and mao-bushi-saishin-to, on therapeutic efficacies of benzoxazinorifamycin KRM-1648 against Mycobacterium avium complex infection induced in mice].
Sato K; Shimizu T; Tomioka H; Kawahara S
Kekkaku; 1998 Aug; 73(8):501-6. PubMed ID: 9780605
[TBL] [Abstract][Full Text] [Related]
4. Effects of benzoxazinorifamycin KRM-1648 on cytokine production at sites of Mycobacterium avium complex infection induced in mice.
Tomioka H; Sato K; Shimizu T; Sano C; Akaki T; Saito H; Fujii K; Hidaka T
Antimicrob Agents Chemother; 1997 Feb; 41(2):357-62. PubMed ID: 9021192
[TBL] [Abstract][Full Text] [Related]
5. [Effects of secretory leukocyte protease inhibitor on the production of some cytokines and nitric oxide by murine peritoneal macrophages in response to lipopolysaccharide stimulation and M. avium complex infection].
Sano C; Shimizu T; Sato K; Ogasawara K; Tomioka H
Kekkaku; 1999 Jul; 74(7):563-70. PubMed ID: 10481411
[TBL] [Abstract][Full Text] [Related]
6. [The expression of ICAM-1 on macrophages stimulated with Mycobacterium avium complex and its control by some regulatory cytokines].
Maw WW; Tomioka H; Sato K; Saito H
Kekkaku; 1996 Oct; 71(10):561-7. PubMed ID: 8936990
[TBL] [Abstract][Full Text] [Related]
7. [Therapeutic effects of benzoxazinorifamycin KRM-1648 administered alone or in combination with glycyrrhizin against Mycobacterium avium complex infection in mice].
Shimizu T; Tomioka H; Sato K; Akaki T; Ogasawara K; Kawahara S
Kekkaku; 1999 Aug; 74(8):617-21. PubMed ID: 10487030
[TBL] [Abstract][Full Text] [Related]
8. [Studies on therapeutic efficacy of a new anti-tuberculous drug, benzoxazinorifamycin, against murine experimental mycobacterial infections: attempt at various regimens and protocols].
Tomioka H; Saito H
Kekkaku; 1994 Nov; 69(11):703-10. PubMed ID: 7837724
[TBL] [Abstract][Full Text] [Related]
9. [Chemoprophylaxis against Mycobacterium avium complex infection induced in mice].
Saito H; Murakami K; Kobayashi K; Gidoh M; Hidaka T; Kwon HH
Kekkaku; 1999 Sep; 74(9):677-81. PubMed ID: 10535281
[TBL] [Abstract][Full Text] [Related]
10. [Therapeutic efficacy of a benzoxazinorifamycin, KRM-1648, in Mycobacterium intracellulare infection induced in mice].
Saito H; Tomioka H; Sato K; Hidaka T
Kekkaku; 1994 Feb; 69(2):59-63. PubMed ID: 8126989
[TBL] [Abstract][Full Text] [Related]
11. [In vivo activities of benzoxazinorifamycin KRM-1648, clarithromycin, and levofloxacin, or combination of KRM-1648 with diclofenac sodium against Mycobacterium avium infection induced in mice].
Akaki T; Sato K; Shimizu T; Tomioka H; Kawahara S
Kekkaku; 1997 Aug; 72(8):491-7. PubMed ID: 9293712
[TBL] [Abstract][Full Text] [Related]
12. Tumor necrosis factor, alone or in combination with IL-2, but not IFN-gamma, is associated with macrophage killing of Mycobacterium avium complex.
Bermudez LE; Young LS
J Immunol; 1988 May; 140(9):3006-13. PubMed ID: 2834450
[TBL] [Abstract][Full Text] [Related]
13. [Therapeutic efficacy of a benzoxazinorifamycin, KRM-1648, administered at the different periods of infection in Mycobacterium intracellulare--infected mice].
Tomioka H; Sato K; Saito H; Hidaka T
Kekkaku; 1993 Oct; 68(10):631-5. PubMed ID: 8255070
[TBL] [Abstract][Full Text] [Related]
14. Effects of the Chinese traditional medicine mao-bushi-saishin-to on therapeutic efficacy of a new benzoxazinorifamycin, KRM-1648, against Mycobacterium avium infection in mice.
Shimizu T; Tomioka H; Sato K; Sano C; Akaki T; Dekio S; Yamada Y; Kamei T; Shibata H; Higashi N
Antimicrob Agents Chemother; 1999 Mar; 43(3):514-9. PubMed ID: 10049260
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapeutic efficacy of a newly synthesized benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex infection induced in mice.
Tomioka H; Saito H; Sato K; Yamane T; Yamashita K; Hosoe K; Fujii K; Hidaka T
Antimicrob Agents Chemother; 1992 Feb; 36(2):387-93. PubMed ID: 1605603
[TBL] [Abstract][Full Text] [Related]
16. Production of transforming growth factor-beta by Mycobacterium avium-infected human macrophages is associated with unresponsiveness to IFN-gamma.
Bermudez LE
J Immunol; 1993 Mar; 150(5):1838-45. PubMed ID: 8436819
[TBL] [Abstract][Full Text] [Related]
17. [Therapeutic efficacy of a benzoxazinorifamycin, KRM-1648, administered in various frequencies per week in Mycobacterium intracellulare-infected mice].
Tomioka H; Sato K; Saito H; Dekio S; Hidaka T
Kekkaku; 1993 Nov; 68(11):683-6. PubMed ID: 8264123
[TBL] [Abstract][Full Text] [Related]
18. IL-10 neutralization augments mouse resistance to systemic Mycobacterium avium infections.
Denis M; Ghadirian E
J Immunol; 1993 Nov; 151(10):5425-30. PubMed ID: 8228235
[TBL] [Abstract][Full Text] [Related]
19. [In vitro antimicrobial activities of quinolones, rifamycins and macrolides against Mycobacterium tuberculosis and M.avium complex: attempt to establish new assay methods which accurately reflect therapeutic effects of test agents in vivo].
Sato K; Tomioka H
Kekkaku; 1999 Jan; 74(1):63-70. PubMed ID: 10067057
[TBL] [Abstract][Full Text] [Related]
20. Mycobacterium avium infection of macrophages results in progressive suppression of interleukin-12 production in vitro and in vivo.
Wagner D; Sangari FJ; Kim S; Petrofsky M; Bermudez LE
J Leukoc Biol; 2002 Jan; 71(1):80-8. PubMed ID: 11781383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
